These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

606 related articles for article (PubMed ID: 37479526)

  • 1. Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for
    Wu Y; Wang Y; Liu X; Liao O; Lou G; Li Y; Wu H; Du Q; Ye J
    BMJ Open; 2023 Jul; 13(7):e072670. PubMed ID: 37479526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China.
    Xie Y; Zhu Z; Wang J; Zhang L; Zhang Z; Lu H; Zeng Z; Chen S; Liu D; Lv N;
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial.
    Shao QQ; Yu XC; Yu M; Ma J; Zhao JB; Yuan L; Qi YB; Hu RB; Wei PR; Xiao W; Lan L; Jia BL; Zhang LZ; Ding SZ
    Helicobacter; 2022 Apr; 27(2):e12876. PubMed ID: 35150597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of quadruple regimen with polaprezinc for gastric
    Wu D; Sun Z; Li T; Tan Q; Sun Y; Chen T; Liu Y; Li J; Jiang H; Yuan Z; Zhao Y; Chen W
    BMJ Open; 2020 Nov; 10(11):e037182. PubMed ID: 33203625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
    Chen S; Shen W; Liu Y; Dong Q; Shi Y
    Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
    Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
    Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
    Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial.
    He XJ; Wang XL; Huang XY; Li DZ; Liu G; Wang W; Li DL
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102052. PubMed ID: 36400418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
    Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
    World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area.
    Qiao C; Li Y; Liu J; Ji C; Qu J; Hu J; Ji R; Wan M; Lin B; Lin M; Qi Q; Zuo X; Li Y
    J Gastroenterol Hepatol; 2021 Sep; 36(9):2383-2388. PubMed ID: 33691344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China.
    Zhou JJ; Shi X; Zheng SP; Tang D; Cai T; Yao Y; Wang F
    Helicobacter; 2020 Dec; 25(6):e12755. PubMed ID: 32914914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
    Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.
    Cheng H; Hu FL
    World J Gastroenterol; 2009 Feb; 15(7):860-4. PubMed ID: 19230048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori.
    Chen XX; Chen YX; Bi HX; Zhao X; Zhang LF; Liu JY; Shi YQ
    J Dig Dis; 2022 Oct; 23(10):568-576. PubMed ID: 36415112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection.
    Liu Q; Qi D; Kang J; Jin Y; Liu W; Gao W; Hou P; Lu J
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):221-5. PubMed ID: 25629566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth, rabeprazole, amoxicillin, and doxycycline as first-line Helicobacter pylori therapy in clinical practice: A pilot study.
    Gu L; Li S; He Y; Chen Y; Jiang Y; Peng Y; Liu X; Yang H
    Helicobacter; 2019 Aug; 24(4):e12594. PubMed ID: 31119830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
    Lu K; Lang C; Zou X; Zang L; Sang W; Feng Q; Mu Y; Liu L; Xu C; Zhao J
    Trials; 2023 Jun; 24(1):413. PubMed ID: 37337241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B; Wang J; Li J; Liu L; Chen Y
    Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
    Ji CR; Liu J; Li YY; Qiao C; Qu JY; Hu JN; Lin MJ; Ji R; Li LX; Zuo XL; Li YQ
    J Dig Dis; 2020 Oct; 21(10):549-557. PubMed ID: 32833285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.